Mediar Therapeutics has dosed the first subject in the Phase II WISPer trial of its investigational therapy, MTX-463, for IPF ...

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

At a panel at CTO West Coast, experts from biopharmaceutical companies outlined innovative strategies to shape the future of ...